Fas Ligand-Mediated Apoptosis in Degenerative Disorders of the Brain

Journal of Clinical Immunology

Volumn 23, Issue 6, 2003, Pages 439-446

  Ethell, Douglas W ^a   Buhler, Lillian A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Grad Prog Biochem Molec Biol   (United States)

Author keywords

Alzheimer's; Apoptosis; EAE; FasL; Multiple sclerosis

Indexed keywords

AMYLOID BETA PROTEIN; FAS ANTIGEN; FAS LIGAND;

ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; APOPTOSIS; ASTROCYTE; CELL ACTIVATION; DEGENERATIVE DISEASE; HUMAN; HUMORAL IMMUNITY; HUNTINGTON CHOREA; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INFLAMMATION; MICROGLIA; MULTIPLE SCLEROSIS; NERVE CELL; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE;

ALZHEIMER DISEASE; ANIMALS; APOPTOSIS; FAS LIGAND PROTEIN; HUMANS; HUNTINGTON DISEASE; MEMBRANE GLYCOPROTEINS; MULTIPLE SCLEROSIS; NEURONS; T-LYMPHOCYTES;

EID: 0842309096     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:JOCI.0000010420.96419.a8     Document Type: Review

References (82)

1. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479-489, 1997
2. Peter ME, Krammer PH: The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 10:26-35, 2003
3. Hemmer B, Archelos JJ, Hartung HP: New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 3:291-301, 2002
4. Swanborg RH: Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clin Immunol Immunopathol 77:4-13, 1995
5. Hartung HP, Kieseier BC: The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol 107:140-147, 2000
6. Wildbaum G, Westermann J, Maor G, Karin N: A targeted DNA vaccine encoding Fas ligand defines its dual role in the regulation of experimental autoimmune encephalomyelitis. J Clin Invest 106: 671-679, 2000
7. Brossart P, Brevan MJ: Selective activation of Fas/Fas ligand-mediated cytotoxicity by a self peptide. J Exp Med 183:2449-2458, 1996
8. Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell F, Lynch DH: Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 181:71-77, 1995
9. Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, Martin SJ, Force WR, Lynch DH, Ware CF, Green DR: Cell-autonomous Fas (CD95)/Fas- ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373:441-444, 1995
10. Dhein J, Walczak H, Baumler C, Debatin K-M, Krammer PH: Autocrine T cell suicide mediated by APO-1/(Fas/CD95). Nature 373:438-441, 1995
11. Ju S-T, Panka DJ, Cui H, Ettinger R, El-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A: Fas (CD95)/FasL interactions required for programmed cell death after T cell activation. Nature 373:444-448, 1995
12. + encephalitogenic T cells. Eur J Immunol 24:2609-2617, 1994
13. Tabi Z, McCombe PA, Pender MP: Antigen-specific down-regulation of myelin basic protein-reactive T cells during spontaneous recovery from experimental autoimmune encephalomyelitis: Further evidence of apoptotic deletion of autoreactive T cells in the central nervous system. Int Immunol 7:967-973, 1995
14. Ishigami T, White CA, Pender MP: Soluble antigen therapy induces apoptosis of autoreactive T cells preferentially in the target organ rather than in the peripheral lymphoid organs. Eur J Immunol 28:1626-1635, 1998
15. Matsumoto Y, Hara N, Tanaka R, Fujiwara M: Immunohistochemical analysis of the rat central nervous system during experimental allergic encephalomyelitis, with special reference to Ia-positive cells with dendritic morphology. J Immunol 136:3668-3676, 1986
16. Ford AL, Foulcher E, Lemckert FA, Sedgwick JD: Microglia induce CD4 T lymphocyte final effector function and death. J Exp Med 184:1737-1745, 1996
17. Matsumoto Y, Ohmori K, Fujiwara M: Immune regulation by brain cells in the central nervous system: Microglia but not astrocytes present myelin basic protein to encephalitogenic T cells under in vivo-mimicking conditions. Immunology 76:209-216, 1992
18. Becher B, Barker PA, Owens T, Antel JP: CD95-CD95L: Can the brain learn from the immune system? Trends Neurosci 21:114-117, 1998
19. Bechmann I, Mor G, Nilsen J, Eliza M, Nitsch R, Naftolin F: FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: Evidence for the existence of an immunological brain barrier. Glia 27:62-74, 1999
20. Frigerio S, Silei V, Ciusani E, Massa G, Lauro GM, Salmaggi A: Modulation of Fas-Ligand (Fas-L) on human microglial cells: An in vitro study. J Neuroimmunol 105:109-114, 2000
21. Flugel A, Schwaiger FW, Neumann H, Medana I, Willem M, Wekerle H, Kreutzberg GW, Graeber MB: Neuronal FasL induces cell death of encephalitogenic T lymphocytes. Brain Pathol 10:353-364, 2000
22. Choi C, Park JY, Lee J, Lim J-H, Shin E-C, Ahn YS, Kim C-H, Kim S-J, Kim J-D, Choi IS, Choi I-H: Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-α, or IFN-γ. J Immunol 162:1889-1895, 1999
23. Pender MP: Activation-induced apoptosis of autoreactive and allore-active T lymphocytes in the target organ as a major mechanism of tolerance. Immunol Cell Biol 77:216-223, 1999
24. Ferguson TA, Green DR, Griffiths TS: Cell death and immune privilege. Int Rev Immunol 21:153-172, 2002
25. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189-1192, 1995
26. Griffith TS, Yu X, Herndon JM, Green DR, Ferguson TA: CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 5:7-16, 1996
27. Sabelko-Downes KA, Cross AH, Russell JH: Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis. J Exp Med 189:1195-1205, 1999
28. Bonetti B, Raine CS: Multiple sclerosis: Oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann Neurol 42:74-84, 1997
29. Huang W-X, Huang MP, Gomes MA, Hillert J: Apoptosis mediators of FasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS. Neurology 55:928-934, 2000
30. Gomes AC, Jonsson G, Mjornheim S, Olsson T, Hillert J, Grandien A: Upregulation of the apoptosis regulators cFLIP, CD95 and CD95 ligand inperipheral blood mononuclear cells in relapsing-remitting multiple sclerosis. J Neuroimmunol 135:126-134, 2003
31. Nagata S: Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: A lesson from the mouse model. J Hum Genet 43:2-8, 1998
32. Nagata S, Suda T: Fas and Fas ligand: Ipr and gld mutations. Immunol Today 16:39-43, 1995
33. Matsuno H, Yudoh K, Watanabe Y, Nakazawa F, Aono H, Kimura T: Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand. J Rheumatol 28:22-28, 2001
34. Mitsiades N, Poulaki V, Mitsiades CS, Anderson KC: Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: New tricks for a (not so) old drug. Expert Opin Investig Drugs 10:1075-1084
35. Vargo-Gogola T, Crawford HC, Fingleton B, Matrisian LM: Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Arch Biochem Biophys 408:155-161, 2002
36. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S: Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 186:2045-2050, 1997
37. Hewson AK, Smith T, Leonard JP, Cuzner ML: Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm Res 44:345-349, 1995
38. Clements JM, Cossins JA, Wells GM, Corkill DJ, Helfrich K, Wood LM, Pigott R, Stabler G, Ward GA, Gearing AJ, Miller KM: Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J Neuroimmunol 74:85-94, 1997
39. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA: Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85:683-693, 1996
40. Silletti S, Kessler T, Goldberg J, Boger DL, Cheresh DA: Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an inorganic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci USA 98:119-124, 2001
41. Seino K, Iwabuchi K, Kayagaki N, Miyata R, Nagaoka I, Matsuzawa A, Fukao K, Yagita H, Okumura: Chemotactic activity of soluble Fas ligand against phagocytes. J Immunol 161:4484-4488, 1998
42. Meyer R, Weissert R, Diem R, Storch MK, de Graaf KL, Kramer B, Bahr M: Acute neuronal apoptosis in a rat model of multiple sclerosis. J Neurosci 21:6214-6220, 2001
43. Ouallet J, Baumann N, Marie Y, Villarroya H: Fas system up-regulation in experimental autoimmune encephalomyelitis. J Neurol Sci 170:96-104, 1999
44. Martin-Villalba A, Herr I, Jeremias I, Hahne M, Brandt R, Vogel J, Schenkel J, Herdegen T, Debatin KM: CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J Neurosci 19:3809-3817, 1999
45. Zurita M, Vaquero J, Zurita I: Presence and significance of CD-95 (Fas/APO1) expression after spinal cord injury. J Neurosurg 94:257-264, 2001
46. Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH: Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 23:406-415, 1997
47. Matsushita K, Wu Y, Qiu J, Lang-Lazdunski L, Hirt L, Waeber C, Hyman BT, Yuan J, Moskowitz MA: Fas receptor and neuronal death after spinal cord ischemia. J Neurosci 20:6879-6887, 2000
48. Ethell DW, Kinloch, R, Green DR: Metalloproteinase shedding of FasL regulates beta-amyloid neurotoxicity. Curr Biol 12:1595-1600, 2002
49. Vassar R, Citron M: Abeta-generating enzymes: Recent advances in beta-and gamma-secreatase research. Neuron 27:419-422, 2000
50. Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, Justice A, McConlogue L, Games D, Freedman SB, Morris RG: A learning deficit relatd to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408:975-979, 2000
51. Selkoe D: Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J Clin Invest 110:1375-1381, 2002
52. Selznick LA, Holtzman DM, Han BH, Goken M, Srinivasan AN, Johnson EM, Roth KA: In situ immunodetection of neuronal caspase-3 activation in Alzheimer's disease. J Neuropathol Exp Neurol 59:1020-1026, 1999
53. Rohn TT, Head E, Su JH, Anderson AJ, Bahr BA, Cotman CW Cribbs DH: Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer's disease. Am J Pathol 158:189-198, 2001
54. Su JH, Zhao M, Anderson AJ, Srinivasan A, Cotman CW: Activated caspase-3 expression in Alzheimer's and aged control brain: Correlation with Alzheimer pathology. Brain Res 898:350-357, 2001
55. Harada J, Sugimoto M: Activation of caspase-3 in beta-amyloid-induced apoptosis of cultured rat cortical neurons. Brain Res 842:311-323, 1999
56. Ivins KJ, Thornton PL, Rohn TT, Cotman CW: Neuronal apoptosis induced by beta-amyloid is mediated by caspase-8. Neurobiol Dis 6:440-449, 1999
57. de la Monte SM, Sohn YK, Wands JR: Correlates of p53-and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J Neurol Sci 152:73-83, 1997
58. Morishima Y, Gotoh Y, Zieg J, Barrett T, Takano H, Flavell R, Davis RJ, Shirasaki Y, Greenberg ME: Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci 21:7551-7560, 2001
59. Tanaka M, Itai T, Adachi M, Nagata S: Downregulation of Fas ligand by shedding. Nat Med 4:31-36, 1998
60. Mogi M, Fukuo K, Yang J, Suhara T, Ogihara T: Hypoxia stimulates release of the soluble form of Fas ligand that inhibits endothelial cell apoptosis. Lab Invest 81:177-184, 2001
61. Asai M, Hattori C, Szabo B, Sasagawa N, Maruyama K, Tanuma S, Ishiura S: Putative function of ADAM9, ADAN10 and ADAM17 as APP alpha-secretase. Biochem Biophys Res Commun 301:231-235, 2003
62. Hartmann D, de Strooper B, Semeels L, Craessaerts K, Herreman A, Annaert W, Umans L, Lubke T, Lena Illert A, von Figura K, Saftig P: The disintegrin/metalloproteinase ADAM 10 is essential for notch signaling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet 11:2615-2624, 2002
63. Black RA: Tumor necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol 34:1-5, 2002
64. Eikelenboom P, Zhan SS, van Gool WA, Allsop D: Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol Sci 15:147-150, 1994
65. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB: In-vivo measurement of microglia in dementia. Lancet 358:461-467, 2001
66. El Khoury J, Hickman SE, Thomas CA, Loike JD, Silverstein SC: Microglia, scavenger receptors, and the pathogensis of Alzheimer's disease. Neurobiol Aging 19:S81-S84, 1998
67. Sly LM, Krzesicki RF, Brashler JR, Buhl AE, McKinley DD, Carter DB, Chin JE: Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res Bull 56:581-588, 2001
68. Spanaus KS, Schlapbach R, Fontana A: TNF-alpha and IFN-gamma render microglia sensitive to Fas ligand-induced apoptosis by induction of Fas expression and downregulation of Bcl-2 and Bcl-XL. Eur J Immunol 28:4398-4408, 1998
69. Schlapbach R, Spanaus KS, Malipiero U, Lens S, Tasinato, Tschopp J, Fontana A: TGF-beta induces the expression of the FLICE inhibitor protein and inhibits Fas-mediated apoptosis of microglia. Eur J Immunol 30:3680-3688, 2000
70. Rescigno M, Piguet V, Valzasina B, Lens S, Zubler R, French L, Kindler V, Tschopp J, Ricciardi-Castagnoli P: Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: A new role for Fas ligand in inflammatory responses. J Exp Med 192:1661-1668, 2000
71. Maedler K, Fontana A, Ris F, Sergeev P, Toso C, Oberholzer J, Lehmann R, Bachmann F, Tasinato A, Spinas GA, Halban P, Donath M: FLIP switches Fas-mediated glucose signaling in human pancreatic β cells from apoptosis to cell replication. Proc Natl Acad Sci USA 99:8236-8241, 2002
72. McGeer PL, McGeer EG: Inflammation of the brain in Alzheimer's disease: Implications for therapy. J Leukoc Biol 56:409-415, 1999
73. Akiyama H, et al.: Inflammation and Alzheimer's disease. Neurobiol Aging 21:383-421, 2000
74. Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, Masliah E: Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci USA 99:10837-10842, 2002
75. McGeer PL, Schultzer M, McGeer EG: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiological studies. Neurology 47:425-432, 1996
76. Aisen PS: Anti-inflammatory agents in Alzheimer's disease. Curr Neurol Neurosci Rep 2:405-409, 2002
77. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D: A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408:979-982, 2000
78. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW: A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 406:982-985, 2000
79. Eikelenboom P, Hoogendijk WJG, Jonker C, van Tilburg W: Immunological mechanisms and the spectrum of psychiatric syndromes in Alzheimer's disease. J Psychiatry Res 36:269-280, 2002
80. Furlan R, Brambilla E, Sanvito F, Roccatagliata L, Olivieri S, Bergami A, Pluchino S, Uccelli A, Comi G, Martino G: Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57BL/6 mice. Brain 126:285-291, 2003
81. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT: Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci 22:7873-7878, 2002
82. Krammer PH: CD95's deadly mission in the immune system. Nature 407:789-795, 2000